Article title: Altered lung metabolism and mitochondrial DAMPs in lung injury due to acute kidney injury Authors: Mark Hepokoski, Jing Wang,Read more
The March 2021 issue of Toxicological Sciences includes exciting toxicology research in biotransformation, toxicokinetics, and pharmacokinetics; genetic and epigenetic toxicology; neurotoxicology; and more.Read more
Article title: Intratubular epithelial-mesenchymal transition and tubular atrophy after kidney injury in mice Authors: Noriyuki Yamashita, Tetsuro Kusaba, Tomohiro Nakata, Aya Tomita,Read more
A new observational study finds patients in the hospital for COVID-19 have high levels of soluble urokinase receptor (suPAR), an immune-derived pathogenic protein that is strongly predictive of kidney injury.Read more
Article title: T95 nucleophosmin phosphorylation as a novel mediator and marker of regulated cell death in acute kidney injury Authors:Read more
Physician-Scientists and other researchers at Rush University Medical Center, in collaboration with colleagues at other institutions, have revealed a new treatment target that may help change the outcome for patients at risk of AKI.Read more
Study suggests a protein called suPAR could be targeted to prevent dreaded kidney complications in patients undergoing common medical procedures.Read more
High levels of protein in a patient’s urine shortly after an episode of acute kidney injury is associated with increased risk of kidney disease progression, providing a valuable tool in predicting those at highest risk for future loss of kidney function.Read more
In patients taking immune checkpoint inhibitors as a treatment for cancer, 17% experienced acute kidney injury (AKI), 8% experienced sustained AKI, and 3% had potential immune checkpoint inhibitor–related AKI.
• Use of proton pump inhibitors, which are commonly used to treat stomach ulcers or acid reflux, was associated with a higher risk of experiencing sustained AKI.